[1] 褚萨萨,刘兴,徐成,等. 艾米替诺福韦治疗65岁以上慢性乙型肝炎及肝硬化患者的有效性及安全性. 中华肝脏病杂志,2024,32(10):904-909. [2] 张婷,邓优,康海燕,等. 恩替卡韦抗病毒治疗的乙型肝炎失代偿期肝硬化患者并发症的再代偿. 中华肝脏病杂志,2023,31(7):692-697. [3] Durazzo M, Ferro A, Navarro-Tableros V M, et al. Current treatment regimens and promising molecular therapies for chronic hepatobiliary diseases. Biomolecules, 2025, 15(1): 121. [4] Huang S C, Liu C J. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives. Clin Mol Hepatol, 2023, 29(2): 320-331. [5] Degasperi E, Anolli M P, Lampertico P. Towards a functional cure for hepatitis B virus: a 2022 update on new antiviral strategies. Viruses, 2022, 14(11): 2404. [6] 赵玉雯,朱传龙. 肝硬化营养不良及肌少症治疗研究进展. 实用肝脏病杂志,2024,27(3):324-328. [7] Yu B, Wang J. The efficacy of parenteral nutrition (PN) and enteral nutrition (EN) supports in cirrhosis: A systematic review and network meta-analysis. Medicine, 2022, 101(3): e28618. [8] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39. [9] Bello K E, Mat Jusoh T N A, Irekeola A A, et al. A recent prevalence of Hepatitis B Virus (HBV) genotypes and subtypes in Asia: A Systematic Review and Meta-Analysis//Healthcare. MDPI, 2023, 11(7): 1011. [10] Zhou R, Yang L, Zhang B, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis. J Viral Hepat, 2023, 30(10): 793-802. [11] Kaewdech A, Charatcharoenwitthaya P, Piratvisuth T. Asian perspective on hepatitis B virus and hepatitis C virus elimination. Viruses, 2024, 17(1): 34. [12] Alam S, Khan M A S, Khan M. Evidence of nucleos (t) ide analogue (NUC) therapy in HBV DNA negative decompensated cirrhosis. Hepatol Int, 2021, 15(4): 1028-1029. [13] Kumar R, Kumar S, Prakash S S. Compensated liver cirrhosis: Natural course and disease-modifying strategies. World J Methodol, 2023, 13(4): 179-193. [14] 蔡南,胡鹏. 慢性乙型肝炎抗病毒治疗新药研究进展. 中华肝脏病杂志,2024,32(4):295-299. [15] Li L Q, Chen E Q.In the era of effective antiviral therapy, long-term dynamic endoscopic monitoring does not seem to be necessary for all CHB patients with compensated cirrhosis. Aliment Pharmacol Therapeut, 2023, 57(12): 1467-1468. [16] Sasaki T, Kakisaka K, Kuroda H, et al. Nutritional management for acute liver failure. Hepatol Res, 2024, 54(8): 736-744. [17] Elsebaie E M, Abdel-Fattah A N, Bakr N A, et al. Principles of nutritional management in patients with liver dysfunction—A narrative review. Livers, 2023, 3(2): 190-218. [18] Xie C, Sun S, Huang H, et al. A hemodynamic study of the relationship between the left and right liver volumes and the blood flow distribution in portal vein branches. Med Phys, 2024, 51(9): 6501-6512. [19] Irshad I, Alqahtani SA, Ikejima K, et al. Energy metabolism: An emerging therapeutic frontier in liver fibrosis. Ann Hepatol, 2025,30(1):101896. [20] Rana A, Malik A, Krishnan V, et al. Doppler hemodynamic liver index and hepatic elastic modulus: Advanced ultrasonographic techniques for non-invasive prediction of esophageal varices in cirrhosis. J Clin Ultrasound, 2022, 50(3): 354-363. |